Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

431
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
431
Cancer Vaccines01:30

Cancer Vaccines

383
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Extracellular vesicles in prostate cancer: current understanding and future perspectives.

Journal of the National Cancer Center·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

European urology·2026
Same author

Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (<i>g</i>-rate) based machine learning model.

medRxiv : the preprint server for health sciences·2026
Same author

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.

JCO precision oncology·2026

Related Experiment Video

Updated: Jul 12, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

263

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

Edward M Schaeffer1, Sandy Srinivas2, Nabil Adra3

  • 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 19, 2023
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines offer a framework for prostate cancer management, detailing workup, risk stratification, and treatment for localized, recurrent, and advanced stages. Key recommendations include androgen deprivation therapy (ADT) with intensification for metastatic castration-sensitive disease.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Last Updated: Jul 12, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

263
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer management requires structured guidelines for diverse clinical scenarios.
  • Current treatment paradigms evolve with new therapeutic options.

Purpose of the Study:

  • To outline the NCCN Guidelines for Prostate Cancer management.
  • To detail the workup, risk stratification, and treatment strategies for various prostate cancer stages.

Main Methods:

  • Review of the NCCN Guidelines for Prostate Cancer.
  • Focus on metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC).

Main Results:

  • Androgen deprivation therapy (ADT) with intensification is recommended for metastatic castration-sensitive prostate cancer.
  • For nonmetastatic CRPC, ADT is continued, potentially with secondary hormone therapies based on PSA doubling time.
  • For mCRPC, ADT is continued with sequential addition of various therapies including hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and targeted therapies.

Conclusions:

  • The NCCN Guidelines provide a comprehensive framework for prostate cancer care.
  • A shared decision-making approach is crucial, considering patient factors and disease characteristics.